Home > Insider Trading > Filing (0001415889-24-012234)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1798749	Aerovate Therapeutics Inc.	AVTE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1185035	P Timothy Noyes	C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-05-01	10,000	$2.14	10,000	No	4	M	Direct
Common Stock	Disposition	2024-05-01	9,035	$20.34	965	No	4	S	Direct
Common Stock	Disposition	2024-05-01	965	$20.87	0	No	4	S	Direct
Common Stock	Disposition	2024-05-01	1,357	$19.91	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-05-01	10,000	$0.00	10,000	$2.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
353,381		2031-04-01	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.855 to $20.85, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.855 to $20.89, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Includes 1,357 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.